PH12022550721A1 - Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma - Google Patents
Dosing regimens for treatment of patients with locally advanced squamous cell carcinomaInfo
- Publication number
- PH12022550721A1 PH12022550721A1 PH1/2022/550721A PH12022550721A PH12022550721A1 PH 12022550721 A1 PH12022550721 A1 PH 12022550721A1 PH 12022550721 A PH12022550721 A PH 12022550721A PH 12022550721 A1 PH12022550721 A1 PH 12022550721A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- cell carcinoma
- squamous cell
- patients
- locally advanced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905703P | 2019-09-25 | 2019-09-25 | |
| US202063016762P | 2020-04-28 | 2020-04-28 | |
| EP20184601 | 2020-07-07 | ||
| PCT/EP2020/076994 WO2021058794A1 (en) | 2019-09-25 | 2020-09-25 | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550721A1 true PH12022550721A1 (en) | 2024-05-13 |
Family
ID=72644266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550721A PH12022550721A1 (en) | 2019-09-25 | 2020-09-25 | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024022275A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2525585T3 (es) | 2006-05-05 | 2014-12-26 | The Regents Of The University Of Michigan | Intermedios para la preparación de miméticos de SMAC bivalentes |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| WO2008014229A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| EP2296650B1 (en) | 2008-05-16 | 2020-05-06 | Novartis AG | Immunomodulation by iap inhibitors |
| US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| EP2493879B1 (en) | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant)) |
| US8859541B2 (en) | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| AU2013306087B2 (en) | 2012-08-23 | 2017-08-10 | The Regents Of The University Of Michigan | Bivalent inhibitors of IAP proteins and therapeutic methods using the same |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| WO2014121178A1 (en) | 2013-02-04 | 2014-08-07 | Tetralogic Pharmaceuticals Corp. | Smac mimetic method of treatment |
| US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
| US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| AU2015360095B2 (en) * | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| CA2916970A1 (en) | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
| EP3419643A4 (en) | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
| CN110475567A (zh) | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| WO2019122941A1 (en) * | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
-
2020
- 2020-09-25 AU AU2020356356A patent/AU2020356356A1/en not_active Abandoned
- 2020-09-25 CA CA3151770A patent/CA3151770A1/en active Pending
- 2020-09-25 CN CN202080079488.5A patent/CN114727984A/zh active Pending
- 2020-09-25 WO PCT/EP2020/076994 patent/WO2021058794A1/en not_active Ceased
- 2020-09-25 MX MX2022003628A patent/MX2022003628A/es unknown
- 2020-09-25 EP EP20780195.2A patent/EP4034102A1/en not_active Withdrawn
- 2020-09-25 US US17/761,503 patent/US20250268863A1/en not_active Abandoned
- 2020-09-25 BR BR112022005624A patent/BR112022005624A2/pt not_active IP Right Cessation
- 2020-09-25 PH PH1/2022/550721A patent/PH12022550721A1/en unknown
- 2020-09-25 JP JP2022518772A patent/JP2022550037A/ja active Pending
- 2020-09-25 KR KR1020227013744A patent/KR20220088700A/ko not_active Ceased
-
2022
- 2022-03-24 IL IL291682A patent/IL291682A/en unknown
- 2022-04-20 CO CONC2022/0004947A patent/CO2022004947A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250268863A1 (en) | 2025-08-28 |
| AU2020356356A1 (en) | 2022-05-12 |
| IL291682A (en) | 2022-05-01 |
| MX2022003628A (es) | 2022-07-21 |
| CA3151770A1 (en) | 2021-04-01 |
| CO2022004947A2 (es) | 2022-08-30 |
| EP4034102A1 (en) | 2022-08-03 |
| CN114727984A (zh) | 2022-07-08 |
| KR20220088700A (ko) | 2022-06-28 |
| WO2021058794A1 (en) | 2021-04-01 |
| JP2022550037A (ja) | 2022-11-30 |
| BR112022005624A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX2024010140A (es) | Nuevos metodos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| EP4378524A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| BR112017000556A2 (pt) | terapia de combinação para câncer | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente | |
| TW201642906A (en) | Fixed dose combination for pain relief without edema | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |